Concord Biotech has debuted at Rs 900.05 on the BSE, up by 159.05 points or 21.46% from its issue price of Rs 741.
The scrip is currently trading at Rs 937.00, up by 196.00 points or 26.45% from its issue price. It has touched a high and low of Rs 987.05 and Rs 900.00 respectively. So far 12.88 lakh shares were traded on the counter.
The offering, which was open for subscription between August 4, 2023 and August 8, 2023 was subscribed 24.87 times. The issue price was fixed at Rs 741 per share i.e. at upper end of price band of Rs 705-741 apiece.
Concord is among the leading manufacturers of fermentation-based biopharmaceutical APIs, focused on niche segments, such as immunosuppressant, oncology, anti-fungal and anti-bacterial. It has three manufacturing facilities at Valthera, Dholka, and Limbasi, in Gujarat.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: